2021 Digital RESI Early Stage Investments on line 數位投資上線

"Buffalo Biomedical Technology co., Ltd." participated in the 2021 Digital RESI conference and reported the company's current status and future plans to investors .

Buffalo Biotech is a pre-clinical-stage company offering novel lung lavage therapeutics (Vigor® solution) for acute respiratory distress syndrome (ARDS), and Buffalo Biotech is the first to develop a unique physical therapy method to overcome no pharmacologic therapy problem for ARDS. Animal studies demonstrated reductions: 25% PMNL infiltration, 25% intra alveolar edema, and 50% mortality. Buffalo Biotech is seeking a $1.5M USD Pre-series A Round to start Vigor® solution first-in-Human safety clinical trial in Taiwan.